Beta Bionics Inc (NAS:BBNX)

Q1 2025 Beta Bionics Inc Earnings Call Transcript

May 6, 2025 / 08:30 PM GMT

Release Date Price: $11.35 (-2.83%)

Transcript 10-Q8-K

Key Points

Positve

Beta Bionics Inc (BBNX) reported a 36% year-over-year growth in net sales, reaching $17.6 million for Q1 2025.
The company saw a 48% increase in new patient starts, with 3,853 new patients adopting the islet in Q1.
The pharmacy channel adoption exceeded expectations, with over 20% of new patient starts reimbursed through this channel.
Beta Bionics Inc (BBNX) increased its 2025 annual revenue guidance to $82-$87 million, up from $80-$85 million.
The company is making significant progress in its innovation pipeline, including a patch pump and a bi-hormonal pump, with a target commercialization by the end of 2027.

Negative

Gross margin decreased to 50.9% from 55.7% in Q1 2024, primarily due to the increased pharmacy channel mix.
Operating expenses rose by 66% to $27.6 million, driven by the expansion of the field sales team and costs related to operating as a public company.
The pay-as-you-go pharmacy model results in lower short-term revenue compared to the DME channel.
There is a potential $1 million revenue headwind in 2025 due to the increased pharmacy channel mix.
The company faces seasonal headwinds in new patient starts, which typically decline in Q1 as patients' deductibles reset.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BBNX.OQ - Beta Bionics Inc
Q1 2025 Beta Bionics Inc Earnings Call
May 06, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Beta Bionics first quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentations, there will be a question and answer session. And instructions will follow at that time. As a reminder, please be advised that today's conference is being recorded. I would now like to hand the conference over to Blake Bieber, head of investors relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good afternoon and thank you for joining Beta Bionics first quarter 2025 earnings

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.